{"hq_id":"hq-p-pet-000068","name":"Oral Isoxazoline Flea and Tick Preventive for Dogs (Fluralaner/Sarolaner/Afoxolaner, Seizure Risk in MDR1 Dogs, FDA Alert)","category":{"primary":"pet_care","secondary":"flea_tick_oral","tags":["isoxazoline","fluralaner","Bravecto","sarolaner","Simparica","afoxolaner","NexGard","oral","flea","tick","seizure","MDR1","FDA alert"]},"product_tier":"PET","overall_risk_level":"moderate","description":"Isoxazoline-class oral flea and tick preventives — fluralaner (Bravecto), sarolaner (Simparica), afoxolaner (NexGard), and lotilaner (Credelio) — represent the newest generation of parasiticides, delivered as flavored chewable tablets that provide systemic flea and tick kill for 30-90 days. Isoxazolines selectively inhibit arthropod GABA-gated chloride channels and glutamate-gated chloride channels, causing parasite hyperexcitation and death. In 2018, the FDA issued a safety alert noting reports of neurological adverse events in dogs (muscle tremors, ataxia, seizures), particularly in breeds carrying the MDR1 (ABCB1) gene mutation (Collies, Australian Shepherds, Shelties) that impairs blood-brain barrier efflux of xenobiotics. These remain prescription-only medications requiring veterinary oversight. Despite the FDA alert, isoxazolines are considered safer overall than topical pyrethroids for multi-species households since they eliminate environmental contamination and cross-species contact risk.","synthesis":{"derived_risk_level":"moderate_to_high","synthesis_confidence":0.82,"synthesis_method":"compound_composition","context_used":"human_child","context_source":"product_users_fallback","exposure_modifier":1,"vulnerability_escalated":true,"escalation_reason":"Child exposure group","compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-03-27","synthesis_version":"1.0.0"},"hazard_summary":{"sensitive_populations":"MDR1-mutant dog breeds (Collies, Australian Shepherds, Shelties), dogs with seizure history, puppies under label minimum weight/age","overall_risk":"moderate","primary_concerns":["FDA alert: neurological adverse events including seizures, tremors, and ataxia","MDR1-mutant breeds at elevated risk due to blood-brain barrier P-glycoprotein deficiency","Flavored chewable tablet attractive to children — accidental ingestion risk","Prescription-only but limited pre-treatment MDR1 screening in practice"],"exposure_routes":"Ingestion (oral tablet — systemic distribution via blood). No dermal or environmental exposure pathway (advantage over topicals)."},"exposure":{"routes":["ingestion"],"contact_types":["ingestion_direct"],"users":["pet_dog","child"],"duration":"chronic","frequency":"monthly_to_quarterly","scenarios":["Dog: oral systemic absorption from flavored chewable tablet","MDR1-mutant breeds: impaired blood-brain barrier efflux increases CNS exposure to isoxazoline","Child: accidental ingestion of flavored chewable (designed to be palatable)","No environmental release: systemic action means no topical residue for contact transfer"],"notes":"FDA alert September 2018: neurological adverse events (tremors, ataxia, seizures) reported across all isoxazoline products. MDR1 (ABCB1) mutation: present in ~75% of Collies, 50% of Australian Shepherds, variable in Shelties, Old English Sheepdogs. MDR1 dogs have impaired P-glycoprotein efflux at blood-brain barrier → increased CNS drug exposure. Prescription-only in USA (requires veterinary oversight). Advantage over topicals: no environmental contamination, no cross-species contact risk, no need to separate pets after application."},"consumer_guidance":{"usage_warning":"Discuss your dog's breed and seizure history with your veterinarian before starting isoxazoline treatment. MDR1 gene testing is available ($60-80 via cheek swab) and recommended for herding breeds. Store tablets securely away from children and other pets — flavored chewables are designed to be palatable. Report any neurological signs (tremors, wobbling, seizures) to your veterinarian immediately.","safer_alternatives":["MDR1 testing before treatment to identify at-risk dogs","Topical fipronil for dogs with known MDR1 mutations or seizure history","Amitraz collar (non-systemic, but not for cats or diabetic dogs)","Environmental management (vacuuming, yard treatment) to reduce parasite pressure"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Alert on Isoxazoline Flea and Tick Products — Neurological Adverse Events","citation":"FDA Animal Drug Safety Communication, September 20, 2018; 21 CFR 514","requirements":"FDA required label updates for all isoxazoline products to include seizure and neurological event warnings. Products remain approved as prescription veterinary drugs. Enhanced adverse event reporting under FIFRA Section 6(a)(2) equivalent for animal drugs. Veterinary oversight required for dispensing.","compliance_status":null,"effective_date":"2018-09-20","enforcing_agency":"FDA Center for Veterinary Medicine","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Unused tablets should be returned to veterinarian or disposed via drug take-back programs. Do not flush.","hazardous_waste":false,"expected_lifespan":"30-day (NexGard, Simparica) or 90-day (Bravecto) efficacy per dose"},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000186","compound_name":null,"role":"active_ingredient_class","typical_concentration":"prescription oral; systemic distribution; inhibits arthropod GABA/GluCl channels"}],"identifiers":{"common_names":["oral isoxazoline flea and tick preventive for dogs (fluralaner/sarolaner/afoxolaner, seizure risk in mdr1 dogs, fda alert)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-02T18:30:34.964Z"}}